[Clinical guidelines for stroke].
Shinohara
Yukito
Y
D000925:Anticoagulants / Q000008:administration & dosage; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001120:Arginine / Q000031:analogs & derivatives; D001241:Aspirin / Q000008:administration & dosage; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology; D000077553:Edaravone; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D016166:Free Radical Scavengers / Q000008:administration & dosage; D005990:Glycerol / Q000008:administration & dosage; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007564:Japan; D008689:Methacrylates / Q000008:administration & dosage; D010875:Pipecolic Acids / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D013449:Sulfonamides; D015912:Thrombolytic Therapy; D013997:Time Factors; D014859:Warfarin / Q000008:administration & dosage
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D016166:Free Radical Scavengers; D008689:Methacrylates; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D014859:Warfarin; D001120:Arginine; C031942:argatroban; C034364:ozagrel; D005990:Glycerol; D001241:Aspirin; D000077553:Edaravone; D000983:Antipyrine